BURNABY, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will participate in the following virtual investor conferences:
The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon’s website at www.xenon-pharma.com. When available, webcasts will be posted for replay following the event for 30 days.
About Xenon Pharmaceuticals Inc.
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
MIAMI, FL / ACCESS Newswire / January 8, 2026 / What began as a visionary…
HOUSTON, Jan. 8, 2026 /PRNewswire/ -- Bionova Scientific LLC, an Asahi Kasei company and a…
Company unifies its AI ecosystem under doceree.ai, launches five industry-first AI solutions, earns top global…
SAN FRANCISCO, Jan. 8, 2026 /PRNewswire/ -- Livelong Media is proud to announce Dr. Mark…
CHATTANOOGA, Tenn., Jan. 8, 2026 /PRNewswire/ -- Cleanova, a leading global manufacturer of advanced industrial filtration…
SAN FRANCISCO, Jan. 8, 2026 /PRNewswire/ -- The life sciences industry is buzzing about AI's…